Provided herein are compounds that are able to bind metal ions (e.g., free metal ions or metal ions bound to low affinity ligands) in a sample or subject. Also provided herein are methods of using the compounds for chelating metal ions and for the treatment of diseases associated with abnormal levels of metal ions. Methods of preparing the compounds and pharmaceutical compositions are also provided.

Provided are a display device and a method for manufacturing the same. The display device of an embodiment may include a base layer, a light emitting element, and an encapsulation layer. The encapsulation layer included in the display device may include a first inorganic layer, a second inorganic layer, and an organic layer, and the organic layer may include a near-infrared absorbing dye to contribute to reducing a dead space, and accordingly, the display device may exhibit improved display quality.

The design, synthesis, and functionalization of a conjugate including a tumor-targeting near-infrared (NIR) dye and a therapeutic agent and/or a diagnostic agent, whereby the NIR dye can function to target the therapeutic agent and/or diagnostic agent to tumor cells.

The invention provides agents that target carbonic anhydrase, which can be used as imaging agents or therapeutic agents. The agents can be used to image tumor hypoxia as well as other physiological processes in a subject.

A method of quenching excited state energy from a photodegradable pigment that has been excited by absorption of light having a wavelength in the wavelength range of 290-800 nm, comprising reacting a pigment with a conjugated fused tricyclic compound having electron withdrawing groups of Formula (II) or a salt thereof:

##STR00001## wherein: A is selected from the group consisting of O, S, CO, CS,

##STR00002## B.sup.1, B.sup.2, D.sup.1 and D.sup.2 are each independently selected from the group consisting of F, Cl, Br, I, CF.sub.3, CC13, NR33+, NO2, CN, C(=0)R4, C(O)OR, SO2R5, aryl, and CCHR6; each m independently is 0, 1, 2, 3, or 4; a is 0 or 1; each R is independently selected from the group consisting of LI, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl; R.sup.2 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, and aryl; each R.sup.3 is independently selected from the group consisting of H and C.sub.1-C.sub.6 alkyl; each R.sup.4 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl; each R.sup.5 is independently selected from the group consisting of H, O, OH, NH.sub.2, and Cl; and each R.sup.6 is-independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl.

Novel fluorogenic compounds designed such that upon a chemical event, compounds capable of emitting NIR light are generated, are disclosed. The compounds comprise two or more acceptor-containing moieties and a cleavable donor-containing moiety, being in complete pi-electrons conjugation and being such that no delocalization of pi-electrons is enabled. Also disclosed are fluorescent compounds generated upon subjecting the fluorogenic compounds to a chemical event (e.g., deprotonation). Also disclosed are uses of the fluorogenic compounds as NIR probed with a Turn-ON mechanism in monitoring presence and/or level of various analytes.

A positive-working lithographic printing plate precursor includes a coating optimized for producing a minimum extent of ablation when exposed to heat and/or light. The coating includes an infrared absorbing agent which contains a structural element according to Formula I:

##STR00001##

wherein A represents SR.sup.1 wherein R.sup.1 represents an optionally substituted alkyl, aralkyl, alkaryl, cycloalkyl, alkenyl, alkynyl, aryl, or heteroaryl group, and/or combinations thereof; and Q=CHRCHR, CRCR or CHRCHRCHR and R, R and R independently represent hydrogen, an alkyl, cycloalkyl, aralkyl, alkaryl, aryl or heteroaryl group, or R and R or R and R form together a cyclic structure.

Problem to Be Solved: to provide a chromophore having a far superior nonlinear optical activity to conventional chromophores and to provide a nonlinear optical element comprising said chromophore.

Solution: a chromophore comprising a donor structure D, a -conjugated bridge structure B, and an acceptor structure A, the donor structure D comprising an aryl group substituted with a substituted oxy group; and a nonlinear optical element comprising said chromophore.

This invention relates to new carbocyanine dye compositions, pharmaceutical compositions comprising such compositions, methods of detecting via near infrared fluorescent imaging incipient cancer cells and selective destruction of cancer cells identified by administration of such pharmaceutical compositions. A method of detecting and destroying cancer cells includes introducing a gold dye into an organism suspected of having a cancer cell. The gold dye is a carbocyanine dye covalently attached to a gold nanoparticle. A near infrared light is shined on a region suspected of having the cancer cell. Fluorescence from the gold dye is detected. A beam of radio frequency energy is directed at the region to induce hyperthermia in the cancer cell. The carbocyanine dye has the most basic structure of MHI-148 and structures 6 and 22 with a Au.sub.n[CH.sub.2(CH.sub.2).sub.9CH.sub.2(OCH.sub.2CH.sub.2).sub.4O]COCH.sub.2CH.sub.2-phenyl-O group on a cyclohexene ring that imparts activity to the cancer cell binding and destruction processes.

Photoacoustic voltage dependent dyes and their use in measuring an electrophysiological activity in a subject in vivo are disclosed.